Australia markets closed

PMV Pharmaceuticals, Inc. (PMVP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.6100+0.0300 (+1.90%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 82.82M
Enterprise value -102.09M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.39
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.52
52-week change 3-75.42%
S&P500 52-week change 321.66%
52-week high 39.7200
52-week low 31.1750
50-day moving average 31.7515
200-day moving average 32.0075

Share statistics

Avg vol (3-month) 3495.41k
Avg vol (10-day) 3243.32k
Shares outstanding 551.44M
Implied shares outstanding 651.44M
Float 840.51M
% held by insiders 12.61%
% held by institutions 192.56%
Shares short (28 June 2024) 42.24M
Short ratio (28 June 2024) 43.32
Short % of float (28 June 2024) 45.11%
Short % of shares outstanding (28 June 2024) 44.35%
Shares short (prior month 31 May 2024) 42.55M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-19.41%
Return on equity (ttm)-29.40%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -74.75M
Net income avi to common (ttm)-65.1M
Diluted EPS (ttm)-1.3200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)197.94M
Total cash per share (mrq)3.85
Total debt (mrq)13.02M
Total debt/equity (mrq)6.12%
Current ratio (mrq)16.79
Book value per share (mrq)4.13

Cash flow statement

Operating cash flow (ttm)-56.83M
Levered free cash flow (ttm)-35.33M